Stockwinners Market Radar for March 26, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:04 EDT Cathie Wood's ARK Investment bought 733K shares of Recursion Pharmaceuticals

19:50 EDT Longeveron Inc trading halted, news pending

18:46 EDT GCT Semiconductor and Concord Acquisition Corp III complete business combination - GCT Semiconductor (GCTS) announced the completion of its business combination, previously announced on November 3, 2023 with Concord Acquisition Corp III (CNDB). Concord's sponsor is affiliated with Atlas Merchant Capital, an investment firm that offers debt and equity investment strategies, seeking long-term value through differentiated expertise in financial services and credit markets. Commencing at the opening of trading on March 27, 2024, GCT common shares and warrants to purchase common shares will be listed on the NYSE under the ticker symbols "GCTS" and "GCTSW," respectively. The transaction values GCT at an enterprise value of approximately $461 million, with a total pro forma enterprise value of $667 million, which includes 20.6 million performance-based earnout shares. The transaction has provided the combined company with approximately $50 million of gross proceeds to fuel its continued growth.

18:03 EDT Movella announces Nasdaq notification of planned suspension of trading - Movella Holdings announced that it was notified by the Nasdaq Stock Market of the timing of Nasdaq's planned suspension of trading of the Company's securities. As previously disclosed in its Current Report filed on Form 8-K with the SEC on March 20, the Company notified Nasdaq of the Company's decision to voluntarily delist its shares of common stock, par value 0.001c per share and its warrants exercisable for one share of Common Stock at an exercise price of $11.50 from the Nasdaq Global Market. As disclosed in the 8-K, the Company had expected that the last trading day of the Securities on the Nasdaq Global Market would be on or about April 11. On March 22 however, Nasdaq notified the Company that trading of its Securities would be suspended after the Company files a Form 25 with the SEC on April 1 resulting in the last trading day for the Securities occurring on or about April 1 instead of on or about April 11 as previously thought. The Securities will remain listed on Nasdaq while trading is suspended until the effectiveness of the Form 25 filing on or about April 11 after which time the Securities will be delisted from Nasdaq.

17:31 EDT AZZ Inc. CFO Philip Schlom to retire, Jason Crawford to succeed - AZZ Inc. announced that Philip Schlom, CFO of AZZ, will retire from the company upon completion of his current agreement which concludes on November, 4. Jason Crawford, Senior Vice President - Finance of AZZ Precoat Metals, has agreed to transition into the role of CFO of AZZ Inc. Prior to his current role, Crawford's tenure with Precoat Metals/Sequa Corporation included the roles of Senior Vice President - Finance Sequa Corporation (2020-2022) and Senior Vice President - Finance Precoat Metals (2012-2020).

17:21 EDT General Dynamics awarded $311.19M Navy contract modification - General Dynamics was awarded a $311.19M firm-fixed-price contract action for maintenance, modernization, and repair of the USS Bataan fiscal 2024 docking selected restricted availability. This contract includes options which, if exercised, would bring the cumulative value of this contract to $343.7M. Work is expected to be completed by May 2026. This contract was competitively procured using full and open competition via the System for Award website, with two offers received. Naval Sea Systems Command is the contracting activity.

17:20 EDT Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1 - Roivant Sciences (ROIV) will replace Sunrun (RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations (PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.

16:43 EDT Zevra announces data from the Phase 2 clinical trial of KP1077or SDX for IH - Hypersomnia Zevra Therapeutics announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial evaluating the safety and tolerability of KP1077, serdexmethylphenidate, or SDX , in patients with idiopathic hypersomnia IH . This proof-of-concept study was not powered to demonstrate statistical significance. The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale ESS, Idiopathic Hypersomnia Severity Scale IHSS and Sleep Inertia Visual Analog Scale SIVAS will inform the Phase 3 study design....The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH....The Company plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

16:35 EDT Progress Software considering offer for MariaDB - Progress Software onfirms that it is considering a possible offer for all the issued and to be issued share capital of MariaDB at a value of 60c per share...The terms of the Possible Offer represent: a 9% premium to the possible offer of $0.55 per share made by K1 Capital, announced on February 16, 2024; an 88% premium to MariaDB's average closing share price of the last 30 trading days; and a 216% premium to MariaDB's closing share price on February 5, 2024, the last full trading day prior to the announcement by MariaDB of a potential forbearance agreement with RP Ventures LLC and Hale Capital Partners. Progress believes MariaDB's relational database management RDBMS products offer an attractive value proposition for customers who need a scalable, open-source relational database with the backing of a trusted enterprise software company. Progress has a proven track record in both database management and the ability to collaborate with the open-source community. Progress believes that if it were to make a Firm Offer for MariaDB, this would be in the best interest of all stakeholders. Progress has a track record of delivering on the needs of its customers, as evidenced by its net retention rates of around 100%. Progress has been listed on the Nasdaq for over three decades and has a current market capitalisation of c.$2.3 billion and over $1 billion of capacity to deploy for acquisitions. Progress has an extensive portfolio of infrastructure software products, including database and open-source offerings that are relied upon by major global corporations, and a deep knowledge of the sector in which MariaDB operates. MariaDB is an attractive opportunity for Progress to consider as it meets many aspects of the company's disciplined approach to acquisitions. Progress has undertaken due diligence in order to evaluate a possible offer for all the issued and to be issued share capital of MariaDB.

16:31 EDT Bit Digital receives offer from for Bit Digital AI to expand agreement - Bit Digital announced that it has received a proposal from its existing customer for Bit Digital AI to significantly expand the scope of its existing agreement. The proposal calls for an additional 2,048 GPUs, amounting to a total of 4,096 GPUs under the amended agreement. Bit Digital intends to accept the customer proposal, subject to agreement on certain terms and conditions, at which point it would help the Company towards achieving its goal for its Bit Digital AI business to reach a $100M run-rate for annualized revenue.

16:21 EDT Pioneer Natural executive VP Kleinman sells 4,350 common shares - In a regulatory filing, Pioneer Natural general counsel and executive VP Mark Kleinman disclosed the sale of 4,350 common shares of the company on March 22 at a price of $254.08 per share.

16:18 EDT Li-Cycle announces 17% workforce reduction, CFO to step down - Li-Cycle "provided a business update regarding its organizational structure. As part of its previously disclosed ongoing comprehensive review and Cash Preservation Plan, which includes organizational right-sizing and right-shaping, the Company has made the strategic decision to transition from its regional management structure to a centralized model to better position the Company for future success and increase efficiencies. Tim Johnston, Executive Chair, will transition to the role of interim non-executive Board Chair, where he will provide leadership, support, guidance and strategic advice to the Company. Considering Glencore's nomination rights associated with the recently closed strategic financing, the Nominating and Corporate Governance Committee of the Board will be considering changes to Company's Board and Committee composition, expected to be made immediately following Li-Cycle's next annual general meeting in May 2024. It is expected that these changes will include identifying an independent Board Chair. Conor Spollen, who has been with Li-Cycle since January 2022, has assumed the role of Chief Operating Officer. In this role, Mr. Spollen will be responsible for Li-Cycle's global Spoke operations driving safety, productivity, and cost-efficiency. In addition to overseeing Spoke operations, following the completion of the technical and economic review of the Rochester Hub project, he will be responsible for project delivery and the planned operation of the Rochester Hub. Dawei Li, who has been with Li-Cycle since July 2021, has assumed the new role of Chief Commercial Officer. In his new role, Mr. Li will lead Li-Cycle's global commercial function and consolidate the global team's strategy and approach to continue building strong partnerships with key battery market players. He previously led Li-Cycle's Asia-Pacific region and brings 20 years of experience in strategy and business development and leading growth in untapped markets to drive robust performance. With the changes to the centralized and reduced size of the organization, Debbie Simpson, Chief Financial Officer, will be leaving the Company to pursue new opportunities. In addition to the leadership changes, and as part of the Company's Cash Preservation Plan and the change from a regional to a centralized management model, the Company is taking other steps to reduce its workforce, primarily at the corporate level. Overall, the Company expects to reduce approximately 60 positions, representing approximately 17% of the Company's global workforce. The Company estimates that it will incur total charges of approximately $8.3 million in connection with the workforce reductions, with the majority of these costs to be incurred as cash severance payments over the next twelve months. These steps are expected to generate approximately $10 million in payroll and benefit cost savings on an annualized basis."

16:15 EDT Aptose Biosciences proceeds from closing of public offering Jan 30 $9.7M - On January 30, Aptose closed a public offering of 5,649,122 common shares of the Company and warrants at a combined offering price of $1.71 per share. This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. Total gross proceeds from the public offering were approximately $9.7M before deducting underwriting costs, placement agent commissions and other offering-related expenses.

16:07 EDT Syndax granted Priority Review for NDA for revumenib by FDA - Syndax Pharmaceuticals announced that the FDA has granted Priority Review for its New Drug Application, or NDA, for revumenib, the Company's first-in-class menin inhibitor, for the treatment of adult and pediatric relapsed or refractory, or R/R, KMT2A-rearranged, or KMT2Ar, acute leukemia. The NDA filing is being reviewed under the FDA's Real-Time Oncology Review Program, or RTOR, and has been assigned a Prescription Drug User Fee Act, or PDUFA, target action date of September 26, 2024. RTOR allows for a more efficient review and close engagement between the sponsor and the FDA throughout the submission process, which historically has led to earlier approvals. The NDA submission is supported by positive data from the pivotal AUGMENT-101 trial of revumenib in adult and pediatric patients with KMT2Ar acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). As previously reported, the trial met its primary endpoint at the protocol-defined interim analysis with a complete remission, or CR, or a CR with partial hematological recovery, or CRh, rate of 23% among the 57 efficacy evaluable patients in the pooled KMT2Ar acute leukemia population. 70% of patients who achieved a CR/CRh and were assessed for minimal residual disease, or MRD, were MRD negative.

16:06 EDT Vince Holding CEO Schwefel resigns - Vince Holding Corp. announced that Jack Schwefel has resigned as Chief Executive Officer. The company's Board of Directors has appointed David Stefko, current Director and former Chief Financial Officer of the company, as Interim Chief Executive Officer, effective immediately, and has initiated a search process to identify a permanent Chief Executive Officer. "The Board thanks Jack for his work in positioning Vince for its next chapter of growth and wishes him the best as he pursues other opportunities," said Michael Mardy, Chairman of the Board of Directors. "We are committed to finding a leader who has the skills and vision to continue to keep Vince on its trajectory to achieve its long-term objectives. Through his experience as CFO and as a member of our Board, Dave brings significant understanding of the Company and is well-respected across the organization. Having previously served as Interim CEO during a time of prior transition and amidst the volatility of the Covid-19 pandemic, the Board is confident in Dave's ability to lead the organization during this period." Stefko said, "I am proud to rejoin the leadership team during this transition as we continue to execute our transformation plan and progress our strategic initiatives focused on driving long-term profitable growth." The company remains on track with its profitability objectives for full year 2023. The company is still finalizing its annual closing procedures and expects to report fourth quarter and full year 2023 financial results by late April 2024.

15:04 EDT Brand Engagement Network Inc trading resumes

14:27 EDT ShockWave Medical up 13% to $324.49 after trading resumes

14:20 EDT ShockWave jumps 8% to $311.29 after WSJ report of J&J talks

14:02 EDT International Paper confirms talks with DS Smith about possible offer - International Paper (IP) issued the following statement to the London Stock Exchange: "International Paper Company notes the recent announcement by DS Smith and confirms that it is in discussions with DS Smith regarding a Possible Offer. International Paper confirms that it has made an all-equity proposal (the "Proposal") to acquire the entire issued share capital of DS Smith. Under the terms of the Proposal, DS Smith shareholders would receive 0.1285 shares in International Paper for each share they own in DS Smith resulting in DS Smith shareholders owning approximately 33.8 per cent. of the combined group. Based on the International Paper share price of $40.85 at close of business on 25 March 2024, the terms of the Proposal represent a value of 415 pence and premium of 48 per cent. to DS Smith's undisturbed share price on 7 February 2024 (being the day prior to the commencement of the offer period in respect of DS Smith) of 281 pence per DS Smith share. There is compelling strategic and financial rationale for a combination between International Paper and DS Smith, as it would: create a truly global leader in sustainable packaging solutions that is well positioned in attractive and growing markets; significantly strengthen the combined corrugated packaging business in Europe with greater customer offerings; create the opportunity to integrate the mill and box networks, balance the paper positions, and optimise the supply chains, of the respective companies in Europe and the US; leverage market expertise of two experienced and innovative management teams to further enhance innovation, solutions and sustainability products for all customers; enhance value creating solutions for global customers in attractive fast-moving consumer goods and e-commerce segments; drive significant synergies including higher integration, commercial and operational improvements, and economies of scale across sourcing, supply chain and administration; result in significant value creation for both International Paper and DS Smith shareholders; and result in a combined group with a strong balance sheet that is expected to maintain an investment grade credit rating. There can be no certainty that any offer will ultimately be made for DS Smith. The International Paper Board continues to consider M&A in a disciplined manner and believes an acquisition of DS Smith is aligned with International Paper' strategy to enhance its corrugated packaging business in Europe and would create significant value for both International Paper and DS Smith shareowners. In accordance with Rule 2.6(a) of the U.K. Takeover Code, International Paper is required, by not later than 5.00 p.m. on 23 April 2024, to either announce a firm intention to make an offer for DS Smith in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code. In accordance with Rule 2.5(a) of the U.K. Takeover Code, International Paper reserves the right to make an offer for DS Smith on less favourable terms than those set out in this announcement: (i) with the agreement or recommendation of the DS Smith Board; or (ii) if a third party announces (after the date of this announcement) a firm intention to make an offer or a possible offer for DS Smith which, at that date, is of a value less than the value implied by the Exchange Ratio. International Paper reserves the right to introduce other forms of consideration and/or vary the mix or composition of consideration of any offer. This announcement has been made by International Paper without the prior agreement or approval of DS Smith. A further announcement will be made if and when appropriate."

13:45 EDT Boeing credit ratings placed on review for downgrade by Moody's - Moody's placed the Baa2 senior unsecured rating and Prime-2 short-term rating of Boeing on review for downgrade. The rating outlook was previously stable. "Placing the ratings on review for downgrade follows Moody's belief that Boeing will be unable to deliver 737 narrow-body aircraft at the volumes required for it to materially expand its free cash flow and retire debt in a reasonable timeframe," the ratings agency said in a statement. The aftereffects of the door plug ejection on Alaska Airlines flight 1282 on January 6, and investments in components and parts inventory in an attempt to reduce travelled work in the production of 737s will result in about $4.5B of negative free cash flow in Q1, it points out. Moody's says Boeing's cash will fall well below $10B come March 31.

13:35 EDT DS Smith confirms talks with International Paper about proposal - DS Smith Plc (DITHF) issued the following statement to the London Stock Exchange in response to media speculation: "The Board of DS Smith notes the recent media speculation and confirms that it is in discussions with International Paper Company (IP) regarding a proposal to acquire DS Smith through a possible all share offer. Under the terms of the Proposal, DS Smith shareholders would receive 0.1285 shares in International Paper for each share they own in DS Smith, resulting in DS Smith shareholders owning approximately 33.8 per cent. of the combined International Paper-DS Smith group. Based on International Paper's share price of $40.85 at close of business on 25 March 2024, the terms of the Proposal represent a value of 415 pence and premium of 48 per cent. to DS Smith's closing share price of 281 pence on 7 February 2024, being the day prior to the commencement of the offer period in respect of DS Smith. The Board acknowledges the strategic merits and potential for value creation through a combination with International Paper. Accordingly, the Board is progressing its discussions with International Paper regarding the Proposal. There can be no certainty as to whether any offer will be made by International Paper or the terms of any such offer from International Paper. In accordance with Rule 2.6(a) of the Code, International Paper is required, by not later than 5.00 p.m. on 23 April 2024, either to announce a firm intention to make an offer for DS Smith in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code. Further to the announcement on 7 March 2024, DS Smith is also continuing discussions with Mondi plc (MONDY) regarding a possible all share offer by Mondi for DS Smith. In accordance with Rule 2.6(c) of the Code, Mondi is required, by not later than 5.00 p.m. on 4 April 2024, to either announce a firm intention to make an offer for DS Smith in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer for DS Smith, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code. A further announcement will be made if and when appropriate. This statement is being made by DS Smith without the prior agreement or approval of International Paper."

13:13 EDT International Paper falls 1% after Sky report of possible DS Smith bid - The shares are down 2% to $40.22 in afternoon trading after rising before Sky's report.

12:56 EDT Roche receives FDA approval for molecular test to screen blood donors for malaria - Roche announced the U.S. Food and Drug Administration approval of the cobas Malaria test for use on the cobas 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides a highly sensitive and specific solution to help ensure that infected blood units are removed from the blood supply. The cobas Malaria molecular test screens whole blood samples for the five main species of Plasmodium parasites that are known to cause human infection. The potential value of a molecular donor screening test for malaria is to improve both blood safety and availability. The test is intended for use in screening blood, organ and tissue donors. The test will be available in the United States at the end of Q2 2024. Approval in CE-marked countries is anticipated later this year.

12:52 EDT Consol Energy sinks following collapse of bridge in Baltimore - Shares of companies with exposure to coal are moving lower following the collapse of the Francis Scott Key Bridge in Baltimore. The bridge provides the entryway to the Helen Delich Bentley Port of Baltimore, the largest port in the U.S. for specialized cargo, and is also a gateway for bulk cargo like coal and petroleum products. Baltimore was the top loading location for U.S. thermal coal exports in 2023, according to the U.S. Census Bureau. Consol Energy (CEIX) says on its website that its Baltimore Marine terminal is one of two coal export terminals on the Eastern Seaboard with the ability to serve the largest ocean-going ships in the world, and the only one served by two rail lines. Shares of Consol Energy are down 8% to $79.86 in afternoon trading while Arch Resources (ARCH) is down 3% and Peabody Energy (BTU) is down 1%.

12:00 EDT Pinstripes falls -14.7% - Pinstripes is down -14.7%, or -61c to $3.53.

12:00 EDT PSQ Holdings rises 9.9% - PSQ Holdings is up 9.9%, or 50c to $5.54.

12:00 EDT Sunnova Energy rises 12.7% - Sunnova Energy is up 12.7%, or 69c to $6.08.

11:02 EDT 3M invess in hydrogen electrolyzer manufacturer EVOLOH - 3M has invested in EVOLOH, a cleantech company that's working to scale up manufacturing of its electrolyzers to make green hydrogen affordable and efficient. Electrolyzers work by using electricity to separate the atoms in water. The result is hydrogen that can be used as clean fuel or chemical reactant to replace fossil fuels in industries that are traditionally difficult to decarbonize or abate, like steel production and aviation. EVOLOH takes an innovative approach to manufacturing electrolyzers with core components that do not require precious metals or rare earth materials and are made from abundant materials like steel, plastic and aluminum. That means lower cost electrolyzer modules for users, as well as lower costs for installation and maintenance. 3M Ventures, the venture capital arm of 3M, recently participated in EVOLOH's $20M Series A fundraising round, which will help the company scale up its manufacturing abilities.

10:32 EDT Ford, Allego announce charging infrastructure partnership for Europe - Ford (F) and Allego N.V. (ALLG) announced a strategic partnership to bring ultra-fast charging infrastructure to hundreds of Ford dealerships across Europe. "The new collaboration will further expand convenient and reliable charging solutions for customers of Ford electric vehicles including the new electric Explorer, as the American brand journeys towards a 100 percent electric line-up of passenger and commercial vehicles in Europe by 2035. Customers can from today order the Explorer crossover, Ford's first EV passenger car engineered and built in Europe. Delivering up to 400 kW charging, Allego ultra-fast charging stations at Ford dealerships will be accessible to EV drivers around the clock and compatible with vehicles that offer DC charging capability regardless of manufacturer," the companies stated.

10:20 EDT Skyward Specialty, New Heights partner to expand crane, millwright capabilities - Skyward Specialty Insurance Group and New Heights Insurance Solutions announced a strategic partnership to expand crane and millwright capabilities for both companies. Through this partnership, New Heights will be Skyward Specialty's lead program administrator for all small sized crane and millwright accounts. Additionally, both New Heights and Skyward Specialty will continue to write medium to large crane and millwright business.

10:12 EDT Epam Systems announces acquisition of Vates, terms not disclosed - EPAM Systems announced its acquisition of Vates S.A., a software development company with offices in Argentina and Chile. Vates will enhance EPAM's software development portfolio and diversify its Latin America delivery capabilities. Vates is an established market leader that delivers end-to-end solutions for leading enterprise clients across multiple industries including finance, healthcare, high-tech, media and telecommunications. Since 1991, it has focused on technology research and innovation to provide services such as custom software development, application testing, digital consulting, system integrations, big data analysis and IT maintenance and support. Vates' global clients include Thomson Reuters, telecommunications giant Claro and financial services provider Bancor.

10:10 EDT Datasea Inc trading resumes

10:05 EDT Carnival orders Excel-class cruise ship for Carnival Cruise Line - Carnival Corporation has signed an agreement with Meyer Werft shipyard for a fifth Excel-class cruise ship for its namesake Carnival Cruise Line brand, with the delivery set for 2028. In mid-February Carnival Corporation had announced the first newbuild order placed in five years with news that a fourth Excel-class ship would join the Carnival Cruise Line fleet in Spring 2027. This announcement confirms an 11th Excel-class ship for the corporation's fleet across four of its world-class brands, and the fifth to be sailed by Carnival Cruise Line. This fifth Excel-class ship will be built on the same platform as its sisters, with the 180,000-ton ship powered by liquefied natural gas and designed to carry over 6,400 guests and 1,800 crew. This order is contingent upon financing, which is expected to be completed later this year.

10:00 EDT Cato Corp. rises 7.5% - Cato Corp. is up 7.5%, or 40c to $5.73.

10:00 EDT Sunnova Energy rises 11.1% - Sunnova Energy is up 11.1%, or 60c to $5.99.

10:00 EDT Consol Energy falls -8.1% - Consol Energy is down -8.1%, or -$7.00 to $79.35.

09:47 EDT Pinstripes falls -5.1% - Pinstripes is down -5.1%, or -21c to $3.93.

09:47 EDT Consol Energy falls -8.5% - Consol Energy is down -8.5%, or -$7.30 to $79.05.

09:47 EDT Cadeler rises 8.5% - Cadeler is up 8.5%, or $1.54 to $19.66.

09:44 EDT M-Tron Industries Inc trading resumes

09:38 EDT California Resources announces expiration of HSR waiting period for Aera deal - In a regulatory filing, California Resources announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired at 11:59 p.m. Eastern Time on March 25, 2024, with respect to the pending combination upon the completion of which Aera Energy, LLC and its operating affiliate Aera Energy Services Company will be indirect wholly-owned subsidiaries of California Resources Corporation. Consummation of the transaction remains subject to other customary conditions, including CRC shareholder approval, prior authorization by the Federal Energy Regulatory Commission under Section 203 of the Federal Power Act and other customary governmental approvals. The transaction is expected to close around mid-year 2024.

09:34 EDT M-Tron Industries Inc trading halted, volatility trading pause

09:31 EDT Cineverse extends partnership with Konami Cross Media NY - Cineverse has announced a multi-year extension of its partnership with Konami Cross Media NY, solidifying the company's position as a leader in the streaming anime landscape. Cineverse will continue its wide distribution of Yu-Gi-Oh!, the popular anime series, providing nearly 400 hours of content to various platforms and channel partners. This new deal includes the recent series, "Yu-Gi-Oh! SEVENS" as well as the 2016 film "Yu-Gi-Oh! The Dark Side of Dimensions". Cineverse also operates a stand-alone "Yu-Gi-Oh!" linear streaming channel, which currently has distribution on Pluto TV, with expansion plans in 2024.

09:28 EDT Rail Vision receives approval from Alstom to install AI Main Line system - Rail Vision Ltd. (RVSN) has received an approval from Alstom (ALSMY) to install the Company's AI-driven Main Line system on Alstom's locomotives. The approval is a part of the previously announced first commercial installation of the Company with a national railways line, Israel Railways. Israel Railways, has purchased ten Rail Vision Main Line system to be installed on Alstom's locomotives.

09:20 EDT Rave Restaurant appoints Jay Rooney as CFO - RAVE Restaurant Group announced a strategic reshaping of its executive team. These appointments represent a significant upgrade to the leadership team, signaling investors and franchisees alike that the company is focused on the continued expansion and development of its Pizza Inn and Pie Five Pizza brands. These new executives include: Jay Rooney, CFO; Zack Viljoen, Vice President of Operations for RAVE and General Manager of Pie Five; Denise Wilson, Associate Vice President of Supply Chain; Carlos Cojulun, Marketing Director of Pizza Inn; Roger Mangum, Director of Operations and Training; Liam Finn, Director of Franchise Development. Rooney joins from Dickey's Barbecue Pit, where he's been CFO since 2018.

09:17 EDT Better Choice Company initiates legal action against Alphia - Better Choice Company initiated a legal action to enforce a right of first refusal option exercised by Alphia, BL4424547, which is controlled by a Paris-based private equity firm, PAI Partners. Pursuant to the terms of a written agreement between Alphia and the Company, Alphia is obligated to acquire the assets of Halo, Purely for Pets, a wholly owned subsidiary of Better Choice. Better Choice seeks to compel the closing of the asset sale and, in the alternative, monetary damages in excess of $19 million caused by Alphia for its misconduct in connection with the ROFR. "After several unsuccessful attempts to communicate with both Winston Song of PAI Partners and David McLain, the CEO of Alphia, and given the significant burden imposed upon Better Choice by Alphia's refusal to close the transaction, Better Choice had no viable option other than to pursue legal action to enforce the terms of the ROFR, as well as all of its rights," stated Better Choice Chairman, Michael Young. The claim has been filed in the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County, Florida.

09:16 EDT Virios Therapeutics announces publication of international patent for IMC-2 - Virios Therapeutics announced that the World Intellectual Property Organization has published Virios' global patent application titled "Valacyclovir and Celecoxib for the Treatment of Alzheimer's and COVID-19", which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.

09:13 EDT Matterport announces Kikkoman used its Digital Twin Platform - Matterport announced that Kikkoman Corporation has used Matterport's Digital Twin Platform to create a digital twin of the company's historic Goyogura soy sauce brewery. Using Matterport's Property Marketing solution, Kikkoman aims to offer factory tours to consumers so that it can be shared with the world. Enriched with notes, guides and videos, the digital twin serves as an educational resource for understanding and preserving the traditions and culture of soy sauce production.

09:11 EDT Progress Software partners with Veeam software - Progress announced a strategic partnership with Veeam Software, the #1 leader by market share in Data Protection and Ransomware Recovery, to provide customers with an enterprise-ready cyber defense solution that strengthens the security of their business-critical data. The partnership between Progress and Veeam combines the intelligent network detection and response capabilities of Progress Flowmon Anomaly Detection System with the security features of Veeam Data Platform. Flowmon ADS provides network layer visibility of potential attacks, so customers can leverage early detection and warnings to trigger the Incident API in Veeam Backup & Replication.

09:10 EDT Future FinTech signs bitcoin mining hosting agreement with Ohio crypto farm - Future Fintech's wholly-owned subsidiary, FTFT SuperComputing, signed a data mining hosting agreement with Teracrypto Technology which stipulates that FTFT SuperComputing will provide hosting services for Teracrypto's bitcoin models on its cryptocurrency farm in Norwalk, Ohio. The Agreement specifies that the maximum total power load that FTFT SuperComputing would provide is 3.0 MW, although FTFT SuperComputing does not guarantee that the total power load will reach this level. The agreement will be in force from March 15, 2024 to February 28, 2028.

09:10 EDT Celsius Holdings plans to expand into Australia and New Zealand - Celsius Holdings announced plans to expand into new international markets, growing the company's global sales and distribution footprint to include Australia and New Zealand. "We're pleased to introduce our refreshing, great tasting and functional Celsius energy drinks to consumers in Australia and New Zealand," said John Fieldly, Celsius Holdings Chairman and CEO. "We expect to continue our international growth at a measured pace, targeting strategically important energy drink markets and employing our proven playbook to build a strong and passionate consumer base." Celsius has selected Suntory Oceania as its exclusive manufacturing, sales and distribution partner in Australia and New Zealand. Celsius previously announced a sales and distribution agreement with Suntory Beverage & Food Great Britain and Ireland, and sales in those markets are expected to begin in the second quarter of 2024.

09:08 EDT Ibex appoints Gunter as Vice President of Business Development - ibex announced that Amanda Gunter has been named Vice President of Business Development. Gunter brings more than a decade of experience as a sales leader in the contact center industry. In her role, Gunter will be responsible for growing new business for ibex and report to John Thompson, Head of Sales at ibex. Before joining ibex, Gunter was at Cyara.

09:08 EDT 180 Degree Capital says Comscore board supports nominee Matthew Mclaughlin - 180 Degree Capital Corp. (TURN) noted the announcement by comScore (SCOR) that SCOR's Nominating Committee and Board of Directors will support the addition of 180 Degree Capital's nominee, Matthew McLaughlin to SCOR's Board of Directors at its upcoming 2024 Annual Meeting of Stockholders. "We commend SCOR's Board for reaching this conclusion and avoiding the need for a competitive proxy contest," said Kevin Rendino, CEO of 180 Degree Capital. "We nominated Matt because we believe his successful tenure as Chief Operating Officer of DoubleVerify Holdings and deep experience in the digital advertising market will bring a much-needed skill set to SCOR's Board along with improved corporate governance as a strong voice for SCOR's common stockholders. We believe SCOR's upcoming Annual Meeting will mark an important step forward toward value creation for SCOR's long-suffering common stockholders with the addition of Jon Carpenter and Matt to SCOR's Board. We hope that SCOR's Board can now focus and reach resolution on outstanding impediments to value creation including SCOR's capital structure, the company's data license contract with its preferred stockholder, Charter Communications, and supporting management's efforts to run SCOR's business in a more efficient, profitable manner than it has in its history."

09:07 EDT Celularity receives HCPCS Q code approval from U.S. CMS for Biovance 3L - Celularity announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has granted a Healthcare Common Procedure Coding System, HCPCS, Q code for Biovance 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds. "The HCPCS Q code approval by CMS further recognizes Biovance 3L as an important therapeutic option for the treatment of wounds," said Dr. Robert Hariri, M.D., Ph.D., Celularity CEO, chairman and founder. "The medical community has been rapidly adopting this product, and the HCPCS Q code approval paves the way for Biovance 3L to realize additional growth, enabling the potential to impact more lives. As one of our leading biomaterial products, we are excited about the potential impact this approval may have on Celularity's performance throughout the remainder of 2024 and beyond. We will continue to innovate in this important part of our business and look forward to providing future updates."

09:05 EDT Intapp announces Warner Nocross + Judd selected DealCloud - Intapp announced that corporate law firm Warner Norcross + Judd LLP has selected DealCloud as its relationship management platform. "As a part of our firmwide growth strategy, we encourage our attorneys to deepen their relationships with current clients while effectively nurturing their networks to source new business," said Tom Smanik, Director of Business Development and Marketing at Warner. "DealCloud will help us facilitate these growth efforts by providing relationship management, intelligence, and outreach capabilities in one platform that's easy for our attorneys to use."

09:04 EDT Microsoft collaborating with Neo4j for GenAI and data solutions - Microsoft announced a collaboration with Neo4j, a Graph Database and Analytics provider, to deliver a unified data offering that addresses customers' critical data needs for Generative AI. Specifically, the collaboration will see Neo4j's graph capabilities natively integrated into Microsoft Fabric and Microsoft Azure OpenAI Service to combine structured and unstructured data, and enable customers to uncover hidden patterns and relationships within their data for better insights and decision-making, as a comprehensive solution. Neo4j's Azure OpenAI Service integration is generally available now. The integration of Neo4j's graph database into Microsoft Fabric will be generally available later this year.

09:03 EDT American Shared Hospital reports passing of founder Ernest Bates - American Shared Hospital Services announced that Company Founder, former Chairman and CEO, and Board Director, Ernest Bates, M.D, passed away on Tuesday, March 19th at the age of 87.

09:02 EDT SenesTech signs distribution agreement with Wilco Distributors - SenesTech announces a signed distribution agreement with Wilco Distributors, a distributor of pest management baits and tools to the rodent pest management market. Wilco Distributors will be a stocking distributor for Evolve soft bait and has placed its initial multi-pallet stocking order.

08:59 EDT Norfolk Southern holder Ancora files proxy statement for director candidates - Ohio-based Ancora Holdings Group announced that it is filing a definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of seven highly qualified director candidates for election to the Company's Board of Directors at the 2024 Annual Meeting of Shareholders scheduled for May 9. Additionally, Ancora sent a letter to shareholders regarding its leadership team's three-year path to superior performance and significant value creation at Norfolk Southern.

08:56 EDT NeoVolta says EOS Linx increased EV deployments by 150% in 2024 - NeoVolta announced that its partner, EOS Linx increased its EV deployments by 150% in 2023. Tennessee-based EOS Linx has been making waves recently thanks to the high deployment rates of its EV charging network. EOS utilizes NeoVolta NV-14 technology in its stations to help provide effective charging solutions for electric vehicles. The company increased its number of nationally-deployed EV charging stations by 150% in 2023 and plans to double its expansion in 2024.

08:51 EDT MasterCard confirms U.S. credit card interchange rate settlement with merchants - Mastercard (MA) announced it has reached an agreement to reduce its U.S. credit card interchange rates for at least a five-year period as part of a legal settlement with merchants. "The settlement, which also features a set of adjustments to Mastercard's network rules, allows small businesses and all merchants to continue to benefit from accepting electronic payments while delivering consumers a simple and secure way to pay," the company stated. The agreement - agreed to by Mastercard, Visa (V) and the court-appointed class counsel - provides all merchants with clarity and certainty on several areas related to their acceptance of payment cards, the company added. "The settlement is subject to final approval by the Eastern District Court of New York. Upon final approval of the class settlement by the court, Mastercard will have resolved the vast majority of all pending U.S. merchant litigations that are directed at seeking changes to the company's interchange structure and merchant acceptance rules. In agreeing to the settlement, Mastercard does not admit to any improper conduct with respect to the plaintiffs' allegations. All rules practice changes will occur after approval of the settlement, most likely in late 2024 or early 2025. This agreement follows a prior settlement with a damages class," MasterCard stated. "This agreement brings closure to a long-standing dispute by delivering substantial certainty and value to business owners, including flexibility in how they manage acceptance of card programs. As the court reviews the settlement, we will focus our energy on continuing to provide consumers, small businesses and all business owners what they expect from Mastercard - a better payments experience, strong value and peace of mind," said Rob Beard, Chief Legal Officer, General Counsel and Head of Global Policy at Mastercard.

08:48 EDT Thumzup enters advertiser partnerships in the Pacific Palisades - Thumzup announced the expansion of its operational footprint into the greater Los Angeles area with new advertiser partnerships in the Pacific Palisades. This expansion to the Pacific Palisades offers Thumzup a lucrative opportunity to broaden its reach and penetrate a new affluent market. By incentivizing users to post about local businesses in this highly coveted neighborhood, the platform enhances user engagement and strengthens its presence in a high-value demographic. This expansion not only aims to drive revenue growth but also solidifies Thumzup's reputation as a versatile and effective advertising solution for local businesses. Among their initial advertisers are Vittorio's Ristorante, a family-owned gem; Moku Sushi, renowned for its Japanese cuisine; Paliskates, a staple in the local skateboarding community; and the Academy of Technology, Art, and Music. Through these partnerships, patrons of each establishment will now have the opportunity to earn monetary rewards by posting about their experiences on Instagram through the Thumzup app.

08:47 EDT Sabre renews technology partnership with HotelREZ - Sabre renewed the technology partnership between HotelREZ, a hotel representation company dedicated to connecting independent properties with bookers worldwide, and Sabre Hospitality. The agreement marks the continuation of the partnership, utilizing Sabre Hospitality's comprehensive suite of products, including Sabre Global Distribution System, SynXis Booking Engine, and Channel Connect, to enhance HotelREZ's extensive range of hospitality solutions across more than 2500 customers.

08:45 EDT American Resources' ReElement partners with U.S. auto manufacturer - American Resources Corporation's ReElement Technologies Corporation announced a commercial partnership with a major U.S. auto manufacturer establishing a highly-efficient and world-leading circular economy for rare earth magnets in the United States. This commercial partnership follows an initial trial program whereby ReElement has showcased its low cost and environmentally friendly process to fully recycle and refine the high value rare-earth elements within EV motors back to ultra-pure magnet-grade rare-earth oxides. This partnership is pioneering a sustainable and truly circular life-cycle solution to ensure that the rare earth elements remain within the domestic supply chain to build in America and stay in America for both commercial and defense applications. ReElement Technologies first produced 99.5% pure neodymium oxide in June of 2021 from end-of-life magnets. Today, we can recycle, separate, purify and refine all of the magnet metals back to 99.5%+ oxide form to commercially supply the domestic magnet supply chain. The company has initially partnered with Advanced Magnetic Labs and USA Rare Earth Magnets LLC and is in conversation with additional domestic magnet producers for the offtake of its rare earth oxides.

08:42 EDT Innodata launches Intelligent Insights feature - Innodata announced the release of Intelligent Insights, a new generative AI-powered media intelligence feature integrated into its PR platform, Agility PR Solutions. Leveraging generative AI technology, Intelligent Insights enables organizations to gather on-the-fly insights from global print, broadcast and social media platforms, contextually analyze specific brand mentions or trends, and perform language translations. The technology aims to increase an organization's efficiency by ensuring executives are equipped with the intelligence needed to make informed decisions for their companies, reputations, brands, products and industry positioning.

08:41 EDT StorageVault Canada completes acquisition of storage asset - STORAGEVAULT CANADA has completed the acquisition of one arm's length storage asset for $10,000,000 in Southwestern Ontario. The total purchase price of the Acquisition, subject to customary adjustments, was paid with funds on hand.

08:39 EDT Gaxos.AI regains compliance with Nasdaq listing requirements - Gaxos.ai announced that it received written notice from the NASDAQ Stock Market on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. On July 10, 2023, NASDAQ notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, NASDAQ has determined that for the Company's common stock had traded above the $1.00 minimum bid price requirement for 10 consecutive trading days as of March 21, 2024. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.

08:38 EDT Alarum appoints Yorai Fainmesser to NetNut Advisory Board - NetNut announced the addition of Mr. Yorai Fainmesser to its Strategic Advisory Board. As a general partner of a leading AI Venture Capital firm, Disruptive AI, and the former Head of the AI and Data Science intelligence unit 8200 in the IDF, Mr. Fainmesser brings unparalleled expertise in AI strategy and cyber technology.

08:37 EDT FDA approves Cerus' 12-month shelf life for INTERCEPT platelet processing sets - Cerus announced that the U.S. Food and Drug Administration FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S. "We are pleased with this successful and timely outcome to our regulatory filing with the FDA to re-establish a longer shelf life for INTERCEPT Platelet Processing Sets in the U.S.," said Vivek Jayaraman, Cerus' chief operating officer. "We expect that this extension will provide relief to our customers' and our supply chains and will give customers the flexibility to balance inventory levels with current and future demand while reducing product expiration risk." The company is continuing to generate additional data to pursue potential shelf life extension from the FDA beyond 12 months for the INTERCEPT Platelet Processing Sets

08:36 EDT Entera Bio announces key milestone for Oral PTH1-34 peptide - Entera Bio announced that The American Society for Bone and Mineral Research, ASBMR, announced on March 25 2024 that the U.S. Food and Drug Administration, FDA, has communicated to the SABRE project team that a ruling to qualify the treatment-related change in bone mineral density as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months. The proposed registrational Phase 3 study for EB613, Entera's lead clinical candidate, which is a first-in-class PTH(1-34) daily tablet treatment for osteoporosis is designed to meet the quantitative BMD thresholds proposed by SABRE.

08:35 EDT CISO Global regains compliance with Nasdaq bid price listing rule - CISO Global announced that as of March 22, 2024, the Nasdaq Stock Market confirmed that the Company has sufficiently demonstrated compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2). CISO Global enacted a reverse split effective on March 8, 2024, and maintained a share price in excess of $1.00 per share for the following 10 consecutive trading days. The Company's March 26, 2024, scheduled hearing before the Nasdaq Hearing Panel has been cancelled.

08:35 EDT AFC Gamma provides Sunburn Cannabis with $34M across credit facilities - AFC Gamma as provided a total of $34M in debt capital across two senior secured credit facilities to High End Holdings and Green Sentry Holdings d/b/a Sunburn Cannabis, a private, vertically integrated, single-state Florida operator. Sunburn intends to use the proceeds from the credit facilities to refinance existing debt, provide working capital, and build additional cultivation and processing facilities and new retail dispensaries in its business plan. AFCG will hold the entire $34M across the two credit facilities, which together consist of a first-lien term loan secured by all assets of Sunburn. AFC Agent served as Agent for this transaction.

08:33 EDT Dyadic International announces publication on study of C1 monoclonal antibody - Dyadic International announced the online publication of the manuscript "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models" in Nature Communications, an international journal publishing peer-reviewed research in all fields of science and technology. "These results demonstrate that the C1-expression system is promising as a technology platform for human monoclonal antibody development and production for preventive and therapeutic medicines," said Prof. Albert Osterhaus of Hannover University of Veterinary Medicine, Germany and of CR2O, a Dutch CRO. "The study characterized the in vitro activity of a monoclonal antibody produced by C1 cells and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication. Those are significant findings, in the sense that the demonstration of HuMab 87G7 in animal models against SARS-CoV-2 provided protection, especially with the raising concerns related to emerging infectious diseases in a changing world."

08:33 EDT KULR Technology enters agreement with Lockheed Martin - KULR Technology (KULR) announces receiving a six-figure contract from Lockheed Martin (LMT) for developing phase change material heat sinks that are pivotal for the thermal regulation of essential electronics within long-range precision missiles. This achievement follows a series of successful evaluations that showcased the efficiency of KULR's solutions in cooling critical onboard systems. With over two decades of pioneering work in heat dissipation technologies, KULR has become a trusted provider for demanding sectors, including defense, aerospace, and beyond. This latest contract with Lockheed Martin underscores KULR's role as a source of innovative cooling solutions.

08:32 EDT APx Acquisition Corp. I signs BCA for AI-driven genomics platform - APx Acquisition Corp. I, OmnigenicsAI - a precision medicine company incubated by Bioceres Group - , and MultiplAI Health - a UK-based AI-enabled preventive medicine company -, have entered into a definitive Business Combination Agreement, or BCA, that would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nasdaq under the ticker symbol "OMNI". The combination creates a global AI-driven genomics company, focused on providing reliable biological data. APx will merge with Heritas Merger Sub, a wholly owned subsidiary of OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI, and APx's ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols "OMNI" and "OMNIW", respectively. The deal values OmnigenicsAI and MultiplAI at a combined enterprise value of approximately $340M at signing.

08:25 EDT Peraso announces mmWave platform for tactical communications - Peraso announced a new wireless platform utilizing the Company's proven mmWave product line for secure tactical communications. This new solution creates an opportunity for Peraso to expand into new markets while also showcasing the practical application benefits of 60 GHz mmWave within the defense sector. Peraso's PRM2136 module offers support for high bandwidth, low latency applications using unlicensed mmWave spectrum and guarantees a high bandwidth connection between the users. Because it operates in the 60 GHz band, there is no interference from traditional Wi-Fi devices operating in the 2.4 and 5 GHz bands. The use of directional beamforming technology, the propagation characteristics of 60GHz signals and advanced software features from Peraso help mitigate interference from other IEEE 802.11ad devices.

08:23 EDT Newmont outlines large epithermal geochemical target at Boleadora - Magna Terra Minerals announced through its 100% owned Argentine subsidiary Atala Resources, that Oroplata, a subsidiary of Newmont Corporation, has provided a detailed summary report of its 2023 exploration program undertaken to date on the Boleadora Project. In addition, Oroplata has made the third anniversary option payment of $150,000 to Atala under the option agreement. Boleadora encompasses ~55,000 hectares in 12 exploration licenses located 17 kilometres southeast along strike from Newmont's Cerro Negro mine along the Margaritas-Boleadoras Corridor, the host to both projects located in Santa Cruz Province, Argentina. Based on 2023 fieldwork, Newmont has identified a 10 by 8 kilometre priority target area, corresponding with previously identified zones 1, 2 and 3 along the Margaritas-Boleadoras Corridor. Assay results from 2023 drainage sediment and rock-chip samples show that anomalous precious metals and pathfinder elements are associated with silica alteration, host fault zones, sinter structures and subtle hyperspectral responses that are indicative of deeper hydrothermal activity and gold mineralization at the Cerro Negro mine. Based on the recent field work, Newmont plans further follow-up exploration activities for 2024.

08:20 EDT Modular Medical appoints Steve Gemmell as VP, engineering - Modular Medical announced the addition of Steve Gemmell as Vice President of Engineering. Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D leadership positions with Cytrellis Biosystems, Inc., Onduo, a joint venture between Sanofi SA and Verily Life Sciences, and Insulet Corporation.

08:18 EDT Sacks Parente Golf introduces incentive program for golf professionals - Sacks Parente Golf introduces its 2024 PGA Professional, Custom Club Fitter, and Golf Instructor Program that is designed to build long-term relationships and additional point-of-sales outlets that can help drive revenue growth. Further, the program should help to introduce more golfers to the Company's advanced putters, which are designed to help shave strokes off of their game. "With our 2024 PGA Professional, Custom Club Fitter, and Golf Instructor Program, we want to incentivize fitters and teachers to offer Sacks Parente premium putters to make the game more enjoyable to golfers who look to them for help with their games. We believe we have removed the initial financial barrier to putting our putters in golfers' hands and then making it financially attractive for instructors and fitters to continue doing so," said Greg Campbell, Executive Chair of SPG.

08:17 EDT Ocean Power secures $1.5M in purchase orders for WAM-V USV's in Latin America - Ocean Power Technologies announced the largest quantity order in the company's history, marking a significant commercial milestone. A valued customer engaged in the offshore energy service industry in Latin America has placed purchase orders for multiple WAM-V USV's, representing a substantial investment totaling over $1.5 million and highlighting OPT's continued expansion in the region. Commenting on this significant achievement, Philipp Stratmann, President, and CEO of Ocean Power Technologies, expressed his enthusiasm, stating, "We are thrilled to see the growing interest and confidence in our technologies, particularly from our strategic partners in Latin America. This order marks a pivotal moment for OPT, highlighting our continued commitment to delivering unparalleled solutions to the region that redefine possibilities in marine robotics."

08:16 EDT Portage Biotech completes monetization of Intensity Therapeutics shares - Portage Biotech (PRTG) has completed selling its equity holding in Intensity Therapeutics (INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monetize its equity holdings in INTS and bring in proceeds, net of related expenses, totaling $2.8M of non-dilutive funding. The Company will use the proceeds to further fund its PORT-6 Phase 1a portion of the ADPORT-601 trial.

08:14 EDT VEON announces sale of stake in Beeline Kyrgyzstan - VEON has signed an agreement for the sale of its 50.1% indirect stake in Beeline Kyrgyzstan to CG Cell Technologies, which is wholly owned by CG Corp Global. The sale is a part of VEON's strategy to simplify the Group's structure and focus on its large markets where it can create scale with its DO1440 digital operator model, providing digital services in finance, entertainment, healthcare and education. The transaction values Beeline Kyrgyzstan's business at 3.4x 2023 EBITDA. Completion of the sale of VEON's stake in Beeline Kyrgyzstan, which is held by VIP Kyrgyzstan Holding AG, to CG Cell Technologies Designated Activity Company is subject to relevant regulatory approvals.

08:10 EDT CareCloud selected by Jersey Hydreight to improve patient exoperience - CareCloud announced that Jersey Hydreight has selected CareCloud's talkUltimate to improve the patient experience and streamline administrative processes. Welcoming Hydreight on board, Justin Pierce, CareCloud's Chief Sales Officer, emphasized, "With seamless lab integration, practice management tools, and revenue cycle management, talkUltimate is a cost-effective option for many medical disciplines. Additionally, it is a Chrome Enterprise recommended solution, signifying that it meets standards set by one of the world's foremost technology companies."

08:09 EDT Japan approves Takeda's ADZYNMA to treat 'ultra-rare' disorder cTTP - Takeda announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMAor apadamtase alfa /cinaxadamtase alfa, for the treatment of congenital thrombotic thrombocytopenic purpura or cTTP, for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme. cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.2 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura or TTP, manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.2,3,4 When left untreated, acute TTP events have a mortality rate of greater than90%.2,4 "The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do. With this approval, we are proud to support the cTTP community with new possibilities and continue our 70-plus year commitment to the rare disease community."

08:09 EDT Genasys partners with European Union-funded project - Genasys announced that it is a partner in Project AWARE, a project funded under the European Union's Horizon Europe Programme that goes beyond smartphone-based alerting by developing a solution that will extend the reception and processing of Galileo Emergency Warning Satellite Service public safety warnings into display panels, indoor warning systems, and acoustic devices. In the next few years, the European Commission will launch the Galileo EWSS, which will utilize a constellation of medium earth orbit satellites to alert people in the event of natural or man-made hazards. The Project AWARE solution will be integrated in fixed devices, including display panels, speakers, long-range acoustic devices and other connected devices which can alert citizens via audio, video, and text alert messages even when telecommunications networks are disrupted or down.

08:08 EDT authID appoints Kunal Mehta to board of directors - authID.ai announced the appointment of Kunal Mehta to its Board of Directors, effective immediately. Mehta, a partner at Bain & Company, adds deep expertise in strategic growth areas targeted by authID: market expansion, go-to-market strategy, and operational efficiency.

08:07 EDT The9 invests in WM Therapeutic GenAI digital precision medicine platform - The9 signed a definitive share purchase agreement with WM Therapeutic, a company operating Generative AI large language model multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares. The9 had invested 8.3% shares of WM Therapeutic in 2021. With the signing of this Agreement, The9 will own 30% of WM Therapeutic. The9 is also granted a purchase option to purchase up to 51% of the total shares of WM Therapeutic under certain conditions. WM Therapeutic develops GenAI large language model brain disease screening platform and digital human personalized psychological consultant, AI precision diagnostic equipment, personalized neuromodulation treatment equipment, Generative AI large language model and AI drug clinical research platform. The9 will pay cash consideration of $1.5M and will issue 251,290,500 restricted Class A ordinary shares to WM Therapeutic. The Class A ordinary shares to be issued to WM Therapeutic will be subject to lock-up conditions and will only be released when the market capitalization of The9 reaches $200M, $500M and $1B. The rest of the restricted shares shall be released from the lock-up when either of the following conditions are met: WM Therapeutic completes a qualified IPO and its shares owned by The9 become freely tradable in the open market; or if and when the The9 exercises its super pro-rata right and, as a result, holds a minimum 51% of the then total share capital of WM Therapeutic.

08:06 EDT Orchestra BioMed appoints David Pacitti to board of directors - Orchestra BioMed announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024. Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers.

08:05 EDT ShiftPixy acquires Northern California provider of human capital,no terms - ShiftPixy announced a definitive agreement to acquire a provider of human capital in Northern California. The company's strong market presence in Northern California has established an annual revenue run rate of $58M an EBITDA of $3.4M, and a significant portfolio of 94 commercial accounts. The company's strategic operations span four regional office locations managing a workforce ecosystem of over 35,800 worksite employees. "This first acquisition represents a pivotal moment for ShiftPixy as we expand our market presence and fortify our position in the Gig Economy," said Scott Absher, CEO of ShiftPixy. "This first in a series of acquisitions is a strategic step to leverage the ShiftPixy technology platform and capture rapid market share in the evolving world of work." The acquisition, poised to enhance ShiftPixy's market dominance, is expected to close in the forthcoming quarter, subject to standard closing conditions. Upon completion, the entity will operate under the ShiftPixy umbrella. The financial details of the acquisition have not been disclosed.

08:04 EDT Inspired announces long-term contract extension with Parkdean Resorts - Inspired Entertainment has signed a long-term contract extension as the provider of arcade games and entertainment products to its longtime partner Parkdean Resorts, the UK's largest holiday park operator. The new agreement solidifies Inspired's position as the leading provider of arcade games and entertainment products to Parkdean Resorts, further enhancing the holiday experience for guests of all ages. As part of the new agreement, Inspired will also provide its cashless arcade technology to Parkdean Resorts, making it even easier for guests to enjoy the wide selection of games and entertainment options available.

08:04 EDT Energous CEO Cesar Johnston no longer serving in that role - Energous announced that Cesar Johnston is no longer serving in his role as president & CEO of Energous, effective immediately. The board of directors has initiated a search to identify a permanent successor. He will remain on the Company's Board of Directors. The board has established an office of the chair, composed of Reynette Au, chair of the board; and Mallorie Burak, CFO, who has also been named principal executive officer for the interim period. The office will oversee strategic planning and direction, working closely with the company's board of directors, board of advisors, senior leadership, partner ecosystem and other stakeholders.

08:02 EDT Aqua Metals, 6K Energy enter supply agreement for lithium battery supply chain - Aqua Metals and 6K Energy announced the signing of a strategic supply agreement, establishing North America's first sustainable circular supply chain for the critical minerals essential for manufacturing lithium-ion batteries. Aqua Metals will deliver sustainably recycled battery materials from its Sierra ARC facility in Reno, NV for 6K Energy to manufacture cathode active material with a low carbon footprint at its PlusCAM facility in Jackson, TN. This supply agreement marks a pioneering step in building North American battery manufacturing capacity that will qualify for domestic content incentives under the Inflation Reduction Act, aligning with the United States' efforts to expand manufacturing capabilities, establish resilient supply chains, and reduce carbon emissions. Based on today's metals prices, the materials supplied under this off-take agreement have an estimated value of more than $50 million annually once 6K Energy's PlusCAM and Aqua Metals' Sierra ARC facilities reach capacity. Starting in 2024, Aqua Metals will supply 6K Energy with sustainably recycled critical minerals, ramping up to provide 30% of the nickel and lithium carbonate needed for 6K Energy's PlusCAM facility. The commitment to utilize up to 30% recycled feedstock presents a unique value proposition, allowing EV and lithium battery manufacturers to benefit from low-carbon, low-cost, and domestically produced cathode materials for the first time. As the United States expands lithium battery manufacturing capacity to nearly one terawatt-hour by 2030, the alliance between Aqua Metals and 6K Energy aims to establish North America's only sustainable closed-loop supply chain for critical battery materials. This first-of-its-kind collaboration addresses the escalating demand for recycling manufacturing scrap and end-of-life batteries, and firmly positions the companies at the forefront of the movement towards a sustainable, resilient, and economically viable battery manufacturing ecosystem in the US. The core of Aqua Metals' and 6K Energy's position as pioneers of a sustainable supply chain lies in their innovative, electrified processes. Both companies utilize technologies that can be powered entirely by clean energy and have a clear pathway to net-zero operations in the future. Each company also eliminates the production of thousands of tonnes of sodium sulfate waste through their patented processes-a byproduct that traditional cathode production and recycling methods generate in significant quantities.

08:00 EDT Microchip announces CEC1736 TrustFLEX devices - As technology and cybersecurity standards continue to evolve, Microchip Technology is helping make embedded security solutions more accessible with its CEC1736 TrustFLEX devices. The CEC1736 Trust Shield family is a microcontroller-based platform root of trust solution enabling cyber resiliency for data centers, telecom, networking, embedded computing and industrial applications. Now, as part of the TrustFLEX platform, the devices are partially configured and provisioned with Microchip-signed Soteria-G3 firmware to reduce the development time needed to integrate platform root of trust. These devices also help fast-track the provisioning of required cryptographic assets and signed firmware images, simplifying the process of secure manufacturing as required by the National Institute of Standards and Technology and Open Compute Project standards.

07:53 EDT GDS Holdings announces $587M equity raise for international business - GDS Holdings announced that GDSH's wholly-owned subsidiary, DigitalLand Holdings, that acts as the holding company for GDSH's international data center assets and operations, has entered into definitive agreements for certain institutional private equity investors to subscribe for $587 million of Series A convertible preferred shares newly issued by GDSI. This transaction is a significant step forward in the Company's strategy to obtain dedicated financing for the development of its international business on a standalone basis. GDS International was established in 2022 with its corporate headquarters in Singapore. Its portfolio currently comprises 330 MW of data center capacity in service and under construction and a further 340 MW held for future development across strategic locations in, among others, Hong Kong, Singapore, Malaysia, and Indonesia. GDSI has secured commitments and reservations from global and China customers for over 200 MW of capacity, of which over 70 MW is already revenue-generating. The Series A subscription price implies a pre-money equity valuation for GDSI of $750 million, which is approximately $3.92 per American Depositary Share of GDSH. GDSI's implied post-money enterprise valuation, including GDSI's forecast net debt of around $935 million at the end of 2024, is around $2.3 billion, which is equivalent to around 24 times GDSI's forecast Adjusted EBITDA for the full year 2025. As of December 31, 2023, GDSH had provided a total of approximately $595 million of inter-company funding to GDSI, comprising approximately $411 million of paid-up share capital and $184 million of shareholder loans and other payables. On a pro forma basis including the proceeds of the Series A new issue, GDSI will have a total paid-up share capital of approximately $1.0 billion and will be sufficiently well-capitalized to complete the development of its current portfolio of data center capacity in service and under construction, without requiring further inter-company funding from GDSH. The shareholder loans and other payables due from GDSI to GDSH at the closing of the transaction will be repaid immediately after the Closing out of the proceeds of the Series A new issue. Post-Closing and on an as-converted basis, GDSH will own approximately 56.1% of the equity interest of GDSI in the form of ordinary shares. The remaining 43.9% equity interest will be held in the form of Series A shares by the Investors, including Hillhouse, Rava Partners, Boyu, Princeville Capital, Tekne Capital, among others. GDSI expects to establish an equity incentive plan which provides for the grant of options exercisable for such number of ordinary shares representing up to 15% of its issued share capital as of the Closing at the Series A subscription price. GDSH and certain Investors will have the right to appoint directors to the Board of GDSI proportionate with their ownership. Mr. William Huang will continue in his role as Chairman of the Board of GDSI. Each Series A share will be entitled to one vote and will be convertible into one ordinary share of GDSI at any time at the holder's option. All Series A shares will automatically convert into ordinary shares of GDSI at, or following, completion of GDSI's IPO, subject to certain conditions.

07:40 EDT Nextech3D.AI receives notice of allowance from USPTO for AI patent - Nextech3D.AI announced that U.S. Patent and Trademark Office has informed of their decision to issue a patent for its technology to generate three-dimensiona) models from two-dimensional images. This is another patent which the Company believes is pivotal to Nextech3D.ai's artificial intelligence technology as it builds a moat around its 3D model making for ecommerce business with industry expertise and intellectual property; which includes its GPT AI powered 3D model generation. This patent approval reinforces and validates Nextech3D.ai's commitment to increasing shareholder value by investing in 3D-AI GPT patents and solutions while simultaneously generating millions in annual 3D modeling revenue. USPTO has sent a letter to the company stating that the patent will be issued on April 2, 202

07:38 EDT Sellas Life Sciences announces data from Phase 2a study of SLS009 - SELLAS Life Sciences Group announces topline data from the Phase 2a study of SLS009 and provides an update on Phase 3 REGAL Study of GPS in AML. The REGAL Steering Committee met on March 22, 2024, to discuss the study and believes the high number of patients who completed participation in the study signals that the interim analysis requiring 60 events may be imminent. The Committee also expressed its satisfaction with SELLAS' overall clinical study conduct and complimented SELLAS for addressing such a debilitating and high unmet medical need as no drugs are approved in the AML CR2 maintenance setting. Summary of Topline Data from Phase 2a data of SLS009 in AML: Patients Characteristics: As of March 15, 2024 data cutoff, 21 patients were treated; All patients were diagnosed with AML refractory to or relapsed after venetoclax containing regimens; 20 out of 21 enrolled patients had adverse/high-risk cytogenetics and 1 patient had intermediate cytogenetics; Median age was 70 and 19/21 of patients were older than 60. Safety: SLS009 in combination with aza/ven has been well-tolerated at all tested dose levels; No dose-limiting toxicities at any of the studied dose levels and no treatment-related high-grade toxicities were observed; Hematologic toxicities profile was consistent with aza/ven standalone treatment. Efficacy: A total of 21 patients were enrolled in the study as of March 15, 2024: 10 in the 45 mg safety cohort, 11 in the 60 mg cohort; 10% response rate in the 45 mg QW safety cohort; 20% response rate in the 60 mg QW cohort; 50% response rate in the 60 mg, 2 x 30 mg BIW cohort; Observed strong anti-leukemic activity, defined as 50% or more bone marrow blast reduction in 67% of patients across all dose levels; Median survival rate has not been reached in any of the dose levels; The first patient enrolled in the study who achieved a complete response continues on the study and remains leukemia-free 9 months after enrollment. Biomarkers: During the trial the Company identified potential biomarkers currently undergoing testing as predictive markers in the most recent portion of the study; Patients with the identified biomarkers exhibited significantly higher response rates: 100% response rate at the optimal dose level; 57% response rate across all dose levels; Furthermore, the Company has clarified the proposed biological basis and mechanism of action for SLS009 activity in patients with these biomarkers; The relevant biomarkers are present in multiple hematologic and solid cancer indications, with a substantial proportion of patients exhibiting them in additional indications, ranging up to ~50% of patients in some indications. The Phase 2a clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with aza/ven at two dose levels, 45 and 60 mg. In the 60 mg dose cohort patients were randomized into either a 60 mg dose once per week or a 30 mg dose two times per week. The target response rate at the optimal dose level is 20% with a target median survival over 3 months. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials.

07:35 EDT Midland announces start of Sonic drilling campaign on Patris property - Midland Exploration announced the start of a Sonic drilling campaign on the Patris gold property, currently 100% owned by Midland and located approximately 30 kilometers to the northeast from the city of Rouyn-Noranda in Quebec. A Sonic drilling campaign is currently underway with two drill and a total of 40 holes have already been completed. Over the next few weeks, 60 new holes will be completed in the eastern part of the Patris property in the Kewagama group. The work is scheduled to be completed in the first week of April. In total, 4,000 meters of sonic drilling are planned in 100 boreholes with a view to characterizing glacial dispersion trails in the till covered with lacustrine clays. The wholly owned Patris project comprises 299 claims covering a surface area of about 117 square kilometers, located less than 10 kilometers northwest of the prolific Doyon/Westwood-Bousquet-La Ronde gold mining camp. The Patris property offers excellent gold potential as it covers the Manneville Fault over more than 8 kilometers and the La Pause Fault over more than 10 kilometers, both recognized as subsidiary faults to the well-known Destor-Porcupine Fault Zone. The Patris property also covers more than 5 kilometers of the fault contact between the sediments of the Kewagama Group and the mafic and ultramafic volcanics of the Malartic Group. Several historical gold showings are found near this contact such as the Gadoury showing which returned 6.3 g/t Au over 1.0 meter and the McDermott showing which returned 8.6 g/t Au over 1.2 meters. A total of 4,000 metres of Sonic drilling is planned in 115 drill holes to characterize geochemical dispersion trains in the glacial till overlain by lacustrine clays. Pursuant to the Transaction, Barrick has the right to acquire up to a 75% interest in the Property in consideration for cash payments totaling C$1,017,500 and exploration work totaling C$16,575,000, over an eight-year period. Barrick is the operator of the work carried out under the Transaction.

07:33 EDT BrightSpring Health announces recent acquisitions driving growth, value - BrightSpring Health Services announced several recent tuck-in acquisitions within its service lines and geographies that continue to support market penetration and market density growth strategies, including a Maryland home health operation, a behavioral therapy company in Michigan and a long-term care pharmacy in Montana. "We are excited to welcome these companies and their employees to our uniquely scaled and differentiated BrightSpring platform consisting of leading and complementary health services," said BrightSpring's President and CEO Jon Rousseau. "These companies share our values and strong commitment to providing top-quality care to high-need patient populations who require it most. Together, we can reach more communities, delivering high-quality services and care directly where people reside."

07:31 EDT Replimune Group announces appointment of Patel to CEO, leadership transitions - Replimune Group announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors. Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer. Additional changes include: Robert Coffin, Ph.D., Founder, President and Chief Research & Development Officer will move to an advisory role as Founder and Chief Scientist and will continue to serve on the Board of Directors. Paul Bullock is being appointed Chief Manufacturing Officer and will assume oversight of manufacturing and lead operations in Framingham and Milton Park in the United Kingdom, following the retirement of Colin Love, Ph.D., Chief Operations Officer, and co-founder, who established our manufacturing operations. Pamela Esposito, Ph.D., Chief Business Officer, and Tanya Lewis, Chief Development Operations Officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity.

07:23 EDT WSP Global acquires Proxion Plan, Proxion Pro, terms not disclosed - WSP Global has acquired Proxion Plan Oy and Proxion Pro Oy, both Finnish companies and subsidiaries of Proxion Oy. With their combined workforce of 150 employees, Proxion Pro and Proxion Plan form one of Finland's largest rail consultancies and offer a range of railway and railway system design services, including traffic and energy services, as well as safety and security expertise. The acquisition adds key rail expertise in Finland to WSP's strong Transport and Infrastructure capabilities in the Nordics and strengthens WSP's market position and ability to lead large-scale projects in the Finnish market.

07:19 EDT Moderna says mRNA-1283 meets primary endpoints in Phase 3 trial - Moderna announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. In the NextCOVE Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills. The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines. The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.

07:15 EDT Cardlytics announces proposed convertible senior notes offering - Cardlytics announced its intention to offer, subject to market and other conditions, $150.0 million aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Cardlytics also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22.5 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of Cardlytics, will accrue interest payable semi-annually in arrears and will mature on April 1, 2029, unless earlier converted or repurchased by Cardlytics. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Cardlytics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Cardlytics' election.

07:11 EDT Bragg Gaming announces review of strategic alternatives - The board of directors confirmed that it has formed an ad hoc special committee, chaired by independent board member Don Robertson, to undertake a review of the company's strategic alternatives. The special committee has been appointed to consider and explore strategic alternatives, which may include the sale of the company or of its assets, a merger, financing, further acquisitions, or other strategic alternatives. No timetable to complete the strategic review process has been established, nor have any decisions been made relating to strategic alternatives at this time. There can be no assurances that any transaction will be completed.

07:11 EDT Home Depot selects Sunnova Energy to provide U.S. solar/battery storage service - Sunnova Energy (NOVA) International announced that it has entered a strategic partnership with The Home Depot (HD) whereby Sunnova will now be the sole provider of solar and battery storage services in The Home Depot stores across the United States and its territories. This groundbreaking agreement will provide consumers with access to the Sunnova Adaptive Home nergy offerings in over 2,000 Home Depot stores. "We are thrilled to become the exclusive provider for home solar and battery storage services for The Home Depot, a company that shares our commitment to providing an unparalleled customer experience," said Michael Grasso, Executive Vice President, Chief Revenue Officer at Sunnova. "Our goal is to make clean, affordable and reliable energy services more accessible to everyone"

07:09 EDT Poet Technologies announces 800G pluggable receiver - POET Technologies announced its first entry into the optical module market for artificial intelligence and cloud data center markets with an 800G pluggable transceiver. The Wavelight is an 800G 2xFR4 OSFP module that incorporates the Company's POET Optical Interposer technology and related optical engine products. Wavelight is the Company's first POET-branded module and its initial entry into the pluggable optical module market, representing a key milestone in its commercialization roadmap. POET debuts in the module market at the leading edge of module designs at a speed and performance that is highly sought after by AI network operators such as Google, Meta, Nvidia and AWS. The Company will showcase Wavelight modules at the OFC 2024 conference in San Diego from March 26-28 and customer sampling will begin in Q3 2024.

07:07 EDT Vigil Neuroscience sees cash runway into 2H25 - Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023. In January 2024, the Company announced that it extended its projected cash runway into the second half of 2025.

07:06 EDT AvidXchange announces board additions, transitions - AvidXchange Holdings announced the appointment of two new Board members - Oni Chukwu and Arthur Rubado. Chukwu was elected by the Board to serve as a Class I director of the Company effective upon the resignation of Murdock. Rubado was elected by the Board to serve as Class III director of the Company effective upon the resignation of Harris. Messrs. Chukwu's and Rubado's terms will expire at the annual meeting of the Company's stockholders to be held in 2025 and 2024, respectively. The appointments maintain the number of directors at nine, eight of whom are independent. Concurrent with the aforementioned additions, AvidXchange announced that Matthew Harris and Wendy Murdock have resigned from the Board and any committees on which they served, effective March 21, 2024.

07:06 EDT Enbridge, MPLX to form JV to connect Permian Basin gas supply to USGC demand - Enbridge (ENB) announced that it has entered into a definitive agreement with WhiteWater/I Squared Capital and MPLX (MPLX) to form a joint-venture that will develop, construct, own, and operate natural gas pipeline and storage assets connecting Permian Basin natural gas supply to growing LNG and U.S. Gulf Coast, or USGC, demand. Approximately 98% of capacity is contracted under long-term, take-or-pay contracts with an average contract length greater than 10 years. Approximately 90% of counterparties are investment grade and include operators in the Permian Basin. Upon closing of the transaction, Enbridge will contribute its wholly-owned Rio Bravo pipeline project and $350M in cash to the joint venture, and will fund the first $150MM of the post-closing capex to complete the Rio Bravo pipeline project. Enbridge will receive a 19% equity interest in the joint venture and retain a 25% economic interest in the Rio Bravo pipeline project. Enbridge will be contributing its Rio Bravo pipeline project, which will extend the joint venture's current infrastructure to serve LNG and other customers on the USGC. Enbridge's share of the post-closing capex to complete the Rio Bravo pipeline project will be 100% of the first $150M and, thereafter, proportionate to its aggregate economic interest in that project. This transaction is expected to unlock future growth opportunities for Enbridge to connect sustainable natural gas production to export markets as part of its USGC strategy. Closing is expected in the second quarter of 2024, subject to receipt of required regulatory approvals and satisfaction of other customary closing conditions.

07:04 EDT Freightos announces new collaboration with Delta Cargo - WebCargo by Freightos is excited to announce a new collaboration with Delta Cargo, enhancing its offering to freight forwarders on Freightos' WebCargo and 7LFreight platforms via expanded access to real-time digital pricing and booking options for Delta Cargo's U.S. export and U.S. domestic air cargo capacity. Delta Cargo is an air cargo belly carrier based in the United States, and their general cargo products and tariff fares have been available for eBooking on WebCargo since 2020. Building on recent technology-driven enhancements that saw Delta Cargo bookings on the platform grow by close to 3X year-over-year, the airline is now expanding the availability of its U.S. export and U.S. domestic fares and capacity on the platform. 7LFreight and WebCargo customers now have access to real-time quotes and capacity for Delta Air Lines' extensive global network out of the United States, reaching more than 250 destinations worldwide. This collaboration also expands the products and services available for booking on the platforms, including Delta Cargo's DASH Heavy for the U.S. domestic market, as well as their General freight and Express Heavy products for U.S. export shipments.

07:02 EDT InspireMD announces abstract one-year follow-up results from C-GUARDIANS trial - InspireMD announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course 2024, which is being held May 28-31, in Leipzig, Germany. Marvin Slosman, chief executive officer of InspireMD, stated, "At last year's VIVA and VEITH conferences in November, Dr. Metzger, principal investigator for the C-GUARDIANS trial, presented positive 30-day follow-up data from the trial which demonstrated a DSMI1 rate of just 0.95% in the Intent-To-Treat analysis population, and 0.63% in the per-protocol analysis population. We are very excited to announce today that an abstract of the 12-month outcomes data from this important trial has been accepted for presentation at the upcoming LINC 2024 conference, which is among the most influential and widely attended meetings focused on vascular intervention."

06:49 EDT e.GO receives Nasdaq delisting notice - Next.e.GO announced that on March 25, the company received a Staff determination letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company of the Staff's determination to delist the company's securities because the company's securities have had a closing bid price below 10c for ten consecutive trading days, which triggers a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In addition to the 10c Rule delisting notice, the company also currently fails to satisfy the requirement that the closing bid price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810(c)(3)(A). The company has received a period of 180 calendar days to return to compliance with the Minimum Bid Price Rule, which compliance period expires on June 10, 2024. If the company's securities fail to regain compliance with the Minimum Bid Price Rule, Nasdaq will have an additional basis for delisting the securities.

06:42 EDT Alibaba announces Cainiao withdraws IPO on Hong Kong Stock Exchange - Alibaba Group announced that its logistics subsidiary Cainiao Smart Logistics Network Limited has withdrawn its initial public offering and listing application on the Hong Kong Stock Exchange. At the same time, Alibaba Group plans to offer to minority shareholders of Cainiao an opportunity to sell all of the outstanding shares of Cainiao held by them to Alibaba Group for 62c per share, representing a total consideration of up to $3.75B. Cainiao shareholders may choose to accept the Offer and sell their shares to Alibaba Group for cash consideration or continue to own Cainiao shares. Alibaba Group owns approximately 63.7% of the fully-diluted equity interest in Cainiao. After completion of the Offer, Alibaba Group plans to align Cainiao's business to better realize strategic synergies with Taobao and Tmall Group and Alibaba International Digital Commerce Group, as well as support Cainiao to execute a long-term strategic expansion of its global logistics network.

06:36 EDT 3M to pay $6B through 2029 to resolve Combat Arms Earplug litigation - 3M announced that, as of the final registration date for the Combat Arms Earplug settlement agreement, more than 99% of claimants are participating in the settlement. Out of a total of more than 293,000 claims, more than 249,000 claimants have registered to participate in the settlement. In addition, more than 41,000 claims have been dismissed by the courts administering the agreements. Once all the settlement registrations that have been submitted by claimants have been processed and validated, 3M anticipates that the settlement will have achieved a more than 99.9% participation level. Under the terms of the agreement, 3M will pay a total amount of up to $6B, between 2023 to 2029, to resolve the litigation, provided all participation thresholds are met. This represents a total pre-tax present value of $5.3B, for which the company has previously recorded reserves. Aearo and 3M are actively engaged in insurance recovery activities to offset a portion of the settlement payments. Formal recovery processes are underway through a lawsuit filed in Delaware, as well as arbitration proceedings.

06:28 EDT Parsons awarded $28M R&D Air Force contract - Parsons was awarded a $28M cost-plus-fixed-fee contract to provide intelligence, surveillance, and reconnaissance command and control and space software baselines for the Air Force Research Laboratory's Global Application Research, Development, Engineering, and Maintenance program. The contract includes one three-year performance period and extends Parsons' portfolio of work supporting the Department of Defense and Intelligence Community, delivering exquisite software capabilities across the all-domain battlespace. The programs leverage Parsons' cyber expertise to identify toolset weaknesses and deliver needed enhancements to meet the needs of the Air Force, DOD, IC, and other federal agency end-users. GARDEM is a $427M multiple-award contract vehicle with a mission to create and implement updated software baselines, allowing federal customers across all domains to assess critical information from multiple data sources. Parsons has won multiple task orders on the contract since it was first awarded in 2019.

06:09 EDT KBR awarded $60.7M task order on Seaport NxG IDIQ contract - KBR was awarded a new one-year $60.7M task order with three one-year options on its Seaport NxG IDIQ contract to assist with project execution for the Naval Information Warfare Center, or NIWC, Atlantic. The contract supports the Defense Health Agency's cybersecurity services and risk management framework initiatives. If all options are exercised, the estimated value of the four-year task order is $245.6M. DHA oversees integrating clinical and business operations across the Military Health System (MHS). The primary focus of the contract is to provide cybersecurity and information assurance services at locations in and outside the Continental U.S. KBR's role with NIWC Atlantic includes assessment and authorization execution, cyber tools development, security control assessments, and cybersecurity sustainment support.

06:04 EDT UPS CEO targets 'bold moves' over next three years - Under a better and bolder approach, UPS will continue its Customer First, People Led, Innovation Driven strategy, and is positioning itself to become the premium small package provider and logistics partner in the world. During the conference, UPS will highlight several strategic initiatives that will enable market share capture and expand its addressable market to drive incremental growth. In addition, the company will share details about how it will lower its cost to serve through its Network of the Future initiative, a plan that will optimize and further automate its core integrated network. "We executed the strategy we set forth nearly three years ago by changing almost every aspect of our business. After coming off a difficult market in 2023, the small package industry is poised to return to growth in 2024 and beyond. Over the next three years, we plan to make bold moves to create a growth flywheel in premium markets, while at the same time drive higher productivity and efficiency," said Carol Tome, UPS CEO. "The growth and productivity initiatives we are executing will result in higher revenue, expanded operating margins and increased free cash flow to deliver long-term value to our shareowners."

05:36 EDT Rio Tinto to contribute $10M to help fund the Minna Oval Development Project - Rio Tinto will contribute $10M to the Shire of Ashburton to help fund the Minna Oval Development Project in Tom Price. The project includes the development of a clubhouse, undercover sports viewing areas, changerooms and toilets, a commercial kitchen and kiosk, and a new shaded playground. These facilities will be used by local sporting organizations and the adjacent North Tom Price Primary school. The Minna Oval Development Project was identified as an important community project through the Shire of Ashburton's Community Lifestyle Infrastructure Plan, which Rio Tinto provided $1M towards. This $10M commitment is in addition to the $37.5M contribution made by Rio Tinto to support the Inspire Community Partnership Agreement over a 10-year period.

05:30 EDT Mesoblast reports FDA notification that MSB-GVHD001 data appears sufficient - Mesoblast announced that FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed biologics license application, or BLA, for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease. Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.

05:23 EDT BlackBerry opens CCoE in Malaysia - BlackBerry opened a Cybersecurity Center of Excellence, or CCoE, in Kuala Lumpur at a ceremony officiated by Prime Minister of Malaysia, YAB Dato' Seri Anwar bin Ibrahim, Canada's Minister of Export Promotion, International Trade and Economic Development, The Honorable Mary Ng, and BlackBerry CEO, John Giamatteo. The new CCoE will deliver cybersecurity training and cyber threat intelligence to help Malaysia and partners in the region better prevent, deter, and respond to cyber threats facing governments and organizations in the Indo-Pacific region.